The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Amid the rapid expansion of the AI-powered healthcare data sector, OneMedNet has announced a significant surge in its operational performance during the first half of the year. According to reports, the company secured over $3 million in new bookings year-to-date in 2026, a figure that already surpasses its total booking volume for the entire 2025 fiscal year. This growth is attributed to the execution of the company's strategy in providing AI-driven Real-World Data (RWD) for regulatory decisions.
This milestone comes as micro-cap medical data firms experience notable growth, driven by institutional demand for AI integration in clinical research. Compared to sector peers like Health Catalyst, which reported a 4% revenue increase in its latest quarter per earnings data, OneMedNet shows strong momentum in its contracting pace despite the relatively small absolute dollar amounts. Analysts note that exceeding the previous year's performance within just six months serves as a positive indicator of the company's business model efficiency in the regulatory data market.
Sign in to access this content
Sign InRegarding market performance, ONMD shares stood at $0.5435 (at close June 12, 2026), trading within a session range of $0.53 to $0.60 according to market data. Investors are now watching the company's ability to convert these bookings into recognized revenue in upcoming financial reports. Additionally, markets are awaiting key US economic data in the coming days, including retail sales and inflation metrics, which may impact risk appetite for micro-cap stocks.